Every material Form 8-K DNA X, Inc. has filed with the SEC since July 02, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
DNA X, Inc. received a letter on August 28, 2026, from a Nasdaq Hearings Panel saying the company has regained compliance with the $2.5 million stockholders' equity requirement. The company's securities remain subject to delisting if it fails to maintain compliance with all Nasdaq listing rules through November 18, 2026, and it is under a mandatory panel monitor until August 28, 2027. If the company falls below the equity requirement again during that period, it would get no compliance plan or extra time, and its securities could be delisted.
Panel determined the company regained compliance with the $2.5 million stockholders' equity requirement; letter dated August 28, 2026
Securities remain subject to delisting if the company fails to maintain compliance with all Nasdaq rules until November 18, 2026
Mandatory panel monitor runs until August 28, 2027; a new equity deficiency would lead to a delisting determination with no cure period
On August 21, 2026, DNA X's compensation committee approved cash awards for all Board members, including CEO Mike Mulica, in place of restricted stock units because not enough shares were available under the company's 2019 Equity Incentive Plan. Each award is tied to a notional grant valued at $60,000 that vests at the earlier of the 2027 annual meeting or a change in control, with the cash payout equal to the stock's value at that time.
Compensation committee approved the cash awards on August 21, 2026.
Each Board member's notional grant is valued at $60,000 at the August 21, 2026 stock price.
Awards vest at the earlier of the 2027 annual meeting of stockholders or a change in control.
The filing says unavailability of shares under the 2019 Equity Incentive Plan prompted the change.
DNA X agreed on June 29, 2026 to sell 1,346,531 shares of non-voting Series B Convertible Preferred Stock to DNA Holdings Venture, Inc., a holder of more than 5% of its stock and an entity associated with director Scott Walker, for $8.1 million. The price is $6.00 per share, paid with $5.0 million in cash and the cancellation of $3.1 million of a convertible note issued in May 2026. The preferred stock converts into common stock after stockholder approval, so the deal can add shares outstanding and dilute existing holders.
1,346,531 Series B preferred shares at $6.00 per share, for an aggregate $8.1 million, including $5.0 million cash and $3.1 million of note balance cancelled
Preferred stock converts to common stock on the first trading day after stockholder approval; it is not convertible before that approval
Company expects to enter a consulting agreement at closing with DNA Holdings, Scott Walker and Brock Pierce for an aggregate 2,494,000 common shares, subject to stockholder approval
Company agreed to file a resale registration statement within 30 calendar days after stockholder approval, and DNA Holdings gets participation rights in future financings for twelve months
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every DNA X, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →